308 studies found for:    United States, Texas | United States, Texas | cook children's
Show Display Options
Rank Status Study
21 Recruiting Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis
Condition: Candidemia
Interventions: Drug: Anidulafungin;   Drug: Fluconazole
22 Available Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
Condition: CD33 Positive Acute Myelogenous Leukemia
Intervention: Biological: Antibody Drug Conjugate Chemotherapeutic
23 Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Conditions: B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
24 Recruiting Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Conditions: Adult B Lymphoblastic Lymphoma;   Childhood B Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Childhood B Lymphoblastic Lymphoma;   Down Syndrome;   Stage I B Lymphoblastic Lymphoma;   Stage II B Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Thioguanine;   Drug: Vincristine Sulfate
25 Recruiting Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia;   Adult T Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
26 Available Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma
Conditions: Recurrent Neuroblastoma;   Neuroblastoma
Interventions: Drug: Fenretinide Lym-X-Sorb Oral Powder;   Drug: Ketoconazole
27 Active, not recruiting National Marrow Donor Program Long-Term Donor Follow-Up
Condition: Hematologic Neoplasms
Intervention:
28 Active, not recruiting Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Condition: Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Interventions: Drug: UX007 (triheptanoin);   Drug: Placebo Oil
29 Recruiting EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult CF Patients
Condition: Cystic Fibrosis
Interventions: Drug: CTX-4430;   Drug: Placebo
30 Active, not recruiting Prospective Cohort for the Evaluation of Biomarkers Following HCT (BMT CTN 1202)
Condition: Allogeneic Hematopoietic Stem Cell Transplantation
Intervention:
31 Completed Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)
Conditions: Vaso-occlusive Crisis;   Sickle Cell Disease
Interventions: Drug: Saline;   Drug: MST-188
32 Recruiting A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Conditions: Hematologic Malignancies;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Inherited Abnormalities of Platelets;   Disorders of the Immune System;   Histiocytic Disorders;   X-linked Lymphoproliferative Syndrome;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
33 Completed Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia
Condition: Catecholaminergic Polymorphic Ventricular Tachycardia
Intervention: Drug: flecainide
34 Terminated Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Conditions: Relapsed T-Cell Acute Lymphoblastic Leukemia;   Relapsed T-Cell Lymphoblastic Lymphoma
Interventions: Drug: Nelarabine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Filgrastim
35 Unknown  Study of Weekly ALTU-238 Compared With Daily Nutropin AQ in Prepubertal Children With Growth Hormone Deficiency
Condition: Growth Hormone Deficiency
Intervention: Drug: Somatropin
36 Completed Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children
Conditions: Septic Shock;   Thrombocytopenia;   Multiple Organ Failure
Intervention:
37 Completed
Has Results
Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
Conditions: Sickle Cell Disease;   Iron Overload;   Hemolytic Anemia
Interventions: Drug: Deferasirox (ICL670);   Drug: Deferoxamine (DFO)
38 Completed
Has Results
Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
Condition: Leukemia, Myelocytic, Acute
Interventions: Drug: Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone;   Drug: Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
39 Completed
Has Results
Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder
Condition: Patent Ductus Arteriosus (PDA)
Interventions: Device: Device closure with AMPLATZER Duct Occluder;   Other: Objective Performance Criteria
40 Completed
Has Results
Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)
Conditions: Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Natural Killer Cell Lymphoblastic Leukemia/Lymphoma
Interventions: Biological: Single Umbilical Cord Blood Unit Transplant;   Biological: Double Umbilical Cord Blood Unit Transplant;   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Cyclosporine A;   Drug: Mycophenolate Mofetil

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.